Oncology | New Developments | CHINA

Hubei Soundny Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Soundny Presents a New Drug-based Alternative in Fight Against Cancer

Lead Product(s): Methotrexate

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

The research highlights a Methotrexate-loaded microvesicles tumor therapy for cholangiocarcinoma, approved for clinical use has shown significant efficacy and safety in the treatment of cholangiocarcinoma.

Phanes Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Phanes Therapeutics Reveals a New Bispecific Antibody Technology Platform at BIO Digital 2020

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

Phanes Therapeutics has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies while maintaining the IgG-like structure.

Shanghai Junshi Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Junshi Biosciences and Merck Announce Collaboration to Explore Promising New Composition Treatment for Head and Neck Cancer Patients

Lead Product(s): Toripalimab,Cetuximab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 01, 2020

Details:

The companies are collaborating for a clinical trial program to investigate the efficacy & safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head & neck.

Yimiao Shenzhou Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Boya Series and Yimiao China Announced that They will Jointly Develop Allogeneic CAR-T Therapy For Cancer Treatment

Lead Product(s): Allogeneic CAR-T therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: EdiGene

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 27, 2020

Details:

Under the terms of the agreement, the two parties will jointly develop potential best-in-class allogeneic CAR-T therapies.

BeiGene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

Lead Product(s): Surufatinib,Tislelizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Hutchison China MediTech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 26, 2020

Details:

Under this agreement, Chi-Med and BeiGene each plan to explore development of the combination of surufatinib with tislelizumab or fruquintinib with tislelizumab in different indications and regions. The companies have agreed to provide mutual drug supply and other support.

Innovent Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Innovent Biologics and MD Anderson Enter a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT in Rare Cancers

Lead Product(s): Sintilimab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: MD Anderson

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 18, 2020

Details:

The collaboration aims at providing opportunities for Innovent to pursue approval of sintilimab by the U.S. FDA for multiple rare cancer indications in addition to larger cancer indications for sintilimab that Innovent is independently pursuing for approval as well.

Gracell Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies

Lead Product(s): GC027

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

GC027 is the first product candidate developed using TruUCAR™ to treat relapsed or refractory (R/R) T-cell malignancies.

Find

Find Novel Oncology Drugs in Clinical Development in CHINA

China

Product Type

Companies

Hubei Soundny Biotechnology

Soundny Presents a New Drug-based Alternative in Fight Against Cancer

Phanes Therapeutics

Phanes Therapeutics Reveals a New Bispecific Antibody Technology Platform at BIO Digital 2020

Shanghai Junshi Biosciences

Junshi Biosciences and Merck Announce Collaboration to Explore Promising New Composition Treatment for Head and Neck Cancer Patients

Yimiao Shenzhou Pharmaceutical

Boya Series and Yimiao China Announced that They will Jointly Develop Allogeneic CAR-T Therapy For Cancer Treatment

BeiGene

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

Innovent Biologics

Innovent Biologics and MD Anderson Enter a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT in Rare Cancers

Gracell Biotechnologies

Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies